The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the ...

Dr. Mehmet Oz, nominated to run the Centers for Medicare & Medicaid Services, will sell shares in Eli Lilly and UnitedHealth.

Dr. Mehmet Oz, nominated to run the Centers for Medicare & Medicaid Services, will sell shares in Eli Lilly and UnitedHealth. Dr. Jay Bhattacharya, NIH nominee, will shed stock in Walmart and Nvidia.

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Barclays reduced their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st ...

I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation ...

This is a great tragedy; many investors will be morally inclined to support Eli Lilly as well as financially. I expect that this moral stance will only help to sustain sentiment for the stock as ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news ...

The institutional investor owned 899 shares of the company’s stock after buying an additional 363 shares during the period. Strategic Financial Concepts LLC’s holdings in Eli Lilly and Company ...